Ashworth, Alan

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature

PARP inhibition in cancer therapyDNA Repair Mechanisms

Cited by 6,683

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature

SARS-CoV-2 and COVID-19 ResearchComputational Drug Discovery Methods

Cited by 4,405

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 3,634

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine

PARP inhibition in cancer therapyProstate Cancer Treatment and Research

Cited by 2,185

BRCAness revisited

Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer

BRCA gene mutations in cancerPARP inhibition in cancer therapy

Cited by 1,257

Resistance to therapy caused by intragenic deletion in BRCA2

Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 1,011

Reprogramming human T cell function and specificity with non-viral genome targeting

Roth, T. L., Puig-Saus, C., Yu, R., Shifrut, E., Carnevale, J., Li, P. J., Hiatt, J., Saco, J., Krystofinski, P., Li, H., et al. (2018) · Nature

CRISPR and Genetic EngineeringCAR-T cell therapy research

Cited by 839

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J. J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., et al. (2018) · Cell

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 733

Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function

Shifrut, E., Carnevale, J., Tobin, V., Roth, T. L., Woo, J. M., Bui, C. T., Li, P. J., Diolaiti, M. E., Ashworth, A., & Marson, A. (2018) · Cell

CRISPR and Genetic EngineeringCAR-T cell therapy research

Cited by 573

The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families

Clark, R. F., Hutton, M., Fuldner, M., Froelich, S., Karran, E., Talbot, C., Crook, R., Lendon, C., Prihar, G., He, C., et al. (1995) · Nature Genetics

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 474

Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence

Belk, J. A., Yao, W., Ly, N., Freitas, K. A., Chen, Y.-T., Shi, Q., Valencia, A. M., Shifrut, E., Kale, N., Yost, K. E., et al. (2022) · Cancer Cell

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 382

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

Williamson, C. T., Miller, R., Pemberton, H. N., Jones, S. E., Campbell, J., Konde, A., Badham, N., Rafiq, R., Brough, R., Gulati, A., et al. (2016) · Nature Communications

Chromatin Remodeling and CancerDNA Repair Mechanisms

Cited by 382

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity

Bajrami, I., Frankum, J. R., Konde, A., Miller, R. E., Rehman, F. L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., et al. (2014) · Cancer Research

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 373

PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer

Chabanon, R. M., Muirhead, G., Krastev, D. B., Adam, J., Morel, D., Garrido, M., Lamb, A., Hénon, C., Dorvault, N., Rouanne, M., et al. (2019) · Journal of Clinical Investigation

PARP inhibition in cancer therapyinterferon and immune responses

Cited by 332

Marked for death: Targeting epigenetic changes in cancer

Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery

Epigenetics and DNA MethylationChromatin Remodeling and Cancer

Cited by 288

Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas

Geyer, F. C., Weigelt, B., Natrajan, R., Lambros, M. B., de Biase, D., Vatcheva, R., Savage, K., Mackay, A., Ashworth, A., & Reis‐Filho, J. S. (2010) · The Journal of Pathology

Cancer Genomics and DiagnosticsBreast Cancer Treatment Studies

Cited by 233

An expanded universe of cancer targets

Hahn, W. C., Bader, J. S., Braun, T. P., Califano, A., Clemons, P. A., Druker, B. J., Ewald, A. J., Fu, H., Jagu, S., Kemp, C. J., et al. (2021) · Cell

Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer

Cited by 213

Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations

Dedes, K. J., Wilkerson, P. M., Wetterskog, D., Weigelt, B., Ashworth, A., & Reis-Filho, J. S. (2011) · Cell Cycle

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 191

LKB1 Haploinsufficiency Cooperates With Kras to Promote Pancreatic Cancer Through Suppression of p21-Dependent Growth Arrest

Morton, J. P., Jamieson, N. B., Karim, S. A., Athineos, D., Ridgway, R. A., Nixon, C., McKay, C. J., Carter, R., Brunton, V. G., Frame, M. C., et al. (2010) · Gastroenterology

Pancreatic and Hepatic Oncology ResearchProtein Kinase Regulation and GTPase Signaling

Cited by 169

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells

Bajrami, I., Kigozi, A., Van Weverwijk, A., Brough, R., Frankum, J., Lord, C. J., & Ashworth, A. (2012) · EMBO Molecular Medicine

PARP inhibition in cancer therapySirtuins and Resveratrol in Medicine

Cited by 136

LKB1 is essential for the proliferation of T‐cell progenitors and mature peripheral T cells

Tamás, P., Macintyre, A., Finlay, D., Clarke, R., Feijoo‐Carnero, C., Ashworth, A., & Cantrell, D. (2010) · European Journal of Immunology

T-cell and B-cell ImmunologyDevelopmental Biology and Gene Regulation

Cited by 94

An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescence.

Rovillain, E., Mansfield, L., Lord, C. J., Ashworth, A., & Jat, P. S. (2011) · BMC Genomics

Telomeres, Telomerase, and SenescenceCancer-related Molecular Pathways

Cited by 43

An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer

Das, R., Sjöström, M., Shrestha, R., Yogodzinski, C., Egusa, E. A., Chesner, L. N., Chen, W. S., Chou, J., Dang, D. K., Swinderman, J. T., et al. (2021) · Nature Communications

Prostate Cancer Treatment and ResearchChromatin Remodeling and Cancer

Cited by 38

Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: A genome-wide interaction study

Rudolph, A., Hein, R., Lindström, S., Beckmann, L., Behrens, S., Liu, J., Aschard, H., Bolla, M. K., Wang, J., Truong, T., et al. (2013) · Endocrine-Related Cancer

Genetic Associations and EpidemiologyMenopause: Health Impacts and Treatments

Cited by 28